Leap Therapeutic Stock Price, News & Analysis

Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.

The news feed for Leap Therapeutics, Inc. (historically Nasdaq: LPTX) captures the company’s transition from a biotechnology issuer focused on targeted and immuno-oncology therapeutics to the renamed Cypherpunk Technologies Inc. with an added digital asset treasury strategy. Press releases describe how the public company changed its name to Cypherpunk Technologies Inc., plans to trade under the ticker CYPH, and intends to acquire and hold Zcash (ZEC) while continuing cancer drug development through a subsidiary that will take the Leap Therapeutics name.

News items cover clinical and preclinical updates for the oncology pipeline, including detailed results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in microsatellite stable colorectal cancer, and preclinical findings for FL-501, a GDF-15–targeting monoclonal antibody associated with cancer cachexia research. Releases describe statistically significant benefits in DKK1-high colorectal cancer subgroups and activity of FL-501 in animal models of cachexia and chemotherapy-induced weight loss.

Investors can also follow strategic and corporate developments such as the initiation of a process to explore strategic alternatives for sirexatamab and FL-501, workforce reductions and restructuring to conserve cash, and the closing of a private placement led by Winklevoss Capital to fund the digital asset treasury strategy. Additional news highlights governance changes, including new board appointments linked to the financing, and the company’s rationale for focusing on Zcash as a privacy-preserving digital asset.

This page brings together these oncology, digital asset, financing, and governance announcements so readers can review how the historical LPTX issuer evolved into Cypherpunk Technologies Inc. and how its cancer programs and Zcash-focused treasury strategy are described in official communications.